US FDA approves updated COVID vaccines for 2026-27 season

FDA approval clears Moderna, Novavax-Sanofi and Pfizer-BioNTech’s updated COVID vaccines, following an advisory panel recommendation to target the dominant XFG variant. The update supports continued vaccine demand and product relevance. Near-term for suppliers, this is a positive regulatory milestone that should bolster sentiment, though broader market impact is likely limited to the involved companies.